Pfizer's Genotropin Shows Positive Results in Study
March 26 2014 - 1:42PM
Dow Jones News
By Tess Stynes
Pfizer Inc. (PFE) said its injectable drug for
small-for-gestational-age children showed statistically significant
increases in height after 24 months in a Phase 3B study.
The study was intended to generate additional data regarding the
safety and efficacy of Genotropin in children born
small-for-gestational-age who fail to achieve catch-up growth by
two years of age.
In the study, which included children between ages 24 months and
30 months, those receiving the drug showed statistically
significant improvement over those who didn't.
Genotropin has U.S. Food and Drug Administration approval to
treat children who don't make enough growth hormone on their own,
those with genetic conditions such as Prader-Willi syndrome and
Turner syndrome, those born smaller than most other babies and
those with idiopathic short stature. The drug also is approved for
adults with growth hormone deficiency.
Write to Tess Stynes at tess.stynes@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
Pfizer (NYSE:PFE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pfizer (NYSE:PFE)
Historical Stock Chart
From Apr 2023 to Apr 2024